Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population
The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug. Eight hundr...
Gespeichert in:
| Veröffentlicht in: | Reproductive biology and endocrinology 2015-07, Vol.13 (1), p.77-77, Article 77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 77 |
| container_title | Reproductive biology and endocrinology |
| container_volume | 13 |
| creator | Revelli, Alberto Pettinau, Grazia Basso, Gemma Carosso, Andrea Ferrero, Alessandro Dallan, Cecilia Canosa, Stefano Gennarelli, Gianluca Guidetti, Daniela Filippini, Claudia Benedetto, Chiara |
| description | The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug.
Eight hundred forty-eight (848) IVF patients classified as expected "poor" or "normal" responders according to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh embryos was calculated by stratifying patients according to the number of retrieved oocytes (1-2, 3-4, 5-6, 7-8, >8).
Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly better pregnancy rate outcome. Patients' characteristics did not significantly differ between the two groups and the better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis, that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively.
When comparing patients with the same number of retrieved oocytes under real-life circumstances, the association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial receptivity could be involved. |
| doi_str_mv | 10.1186/s12958-015-0080-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4514947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541506197</galeid><sourcerecordid>A541506197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-f11db5261ba7dd079aec74584cfa06bb2c03a2bb6d03cfd345702ccbfd5e333a3</originalsourceid><addsrcrecordid>eNptkstu1DAUhiMEohd4ADbIEhs2GewkzoUFUjWiHaRBXRTW1olz0nHl2MGXqfqiPA8ezbR0EMrC0Tn__9k-_rPsHaMLxtr6k2dFx9ucMp5T2tK8fpGdsqpp8qYtmpfP_k-yM-_vKC2SrH6dnRR1QTte8NPs99Ka4KzWOJDrLTgFhtwENUUNQVlD7lXYEIfSTr0yYEJ-ebMis47-qLheka1fkE2ckv07GjtD9KDJlTUw2MSflSE9-LRJYoYNEhOnHh2xY-IEp3C7a1n5ENB_TiUfdfBkdHYiQJyNQRkkUiujZMLODmRQEkmipjaCzrUakcx2Ppz7TfZqBO3x7WE9z35efv2xXOXr66tvy4t1LquuCvnI2NDzomY9NMNAmw5QNhVvKzkCrfu-kLSEou_rgZZyHMqKN7SQsh8HjmVZQnmefdlz59hPOEhMwwQtZqcmcA_CghLHHaM24tZuRcVZOkGTAB8PAGd_RfRBTMpL1BoM2ugFq7uu6mjHuiT98I_0zkZn0vUES49MOW_a8q_qFjQKZcY0fpA7qLjgFeO0Zt1u28V_VOkbcFLSGhxVqh8Z2N4gnfXe4fh0R0bFLoxiH0aRwih2YRR18rx_Ppwnx2P6yj9XvN_j</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1782055783</pqid></control><display><type>article</type><title>Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Revelli, Alberto ; Pettinau, Grazia ; Basso, Gemma ; Carosso, Andrea ; Ferrero, Alessandro ; Dallan, Cecilia ; Canosa, Stefano ; Gennarelli, Gianluca ; Guidetti, Daniela ; Filippini, Claudia ; Benedetto, Chiara</creator><creatorcontrib>Revelli, Alberto ; Pettinau, Grazia ; Basso, Gemma ; Carosso, Andrea ; Ferrero, Alessandro ; Dallan, Cecilia ; Canosa, Stefano ; Gennarelli, Gianluca ; Guidetti, Daniela ; Filippini, Claudia ; Benedetto, Chiara</creatorcontrib><description>The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug.
Eight hundred forty-eight (848) IVF patients classified as expected "poor" or "normal" responders according to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh embryos was calculated by stratifying patients according to the number of retrieved oocytes (1-2, 3-4, 5-6, 7-8, >8).
Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly better pregnancy rate outcome. Patients' characteristics did not significantly differ between the two groups and the better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis, that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively.
When comparing patients with the same number of retrieved oocytes under real-life circumstances, the association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial receptivity could be involved.</description><identifier>ISSN: 1477-7827</identifier><identifier>EISSN: 1477-7827</identifier><identifier>DOI: 10.1186/s12958-015-0080-6</identifier><identifier>PMID: 26209525</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Comparative analysis ; Female ; Follicle Stimulating Hormone - pharmacology ; Follicle Stimulating Hormone - therapeutic use ; Genetic aspects ; Gonadotropin ; Humans ; Luteinizing Hormone - pharmacology ; Luteinizing Hormone - therapeutic use ; Menopause ; Menotropins - pharmacology ; Menotropins - therapeutic use ; Oocyte Retrieval - methods ; Oocytes - drug effects ; Ovulation Induction - methods ; Pharmaceutical industry ; Pregnancy ; Pregnancy Outcome ; Pregnancy Rate ; Recombinant Proteins - pharmacology ; Recombinant Proteins - therapeutic use ; Treatment Outcome</subject><ispartof>Reproductive biology and endocrinology, 2015-07, Vol.13 (1), p.77-77, Article 77</ispartof><rights>COPYRIGHT 2015 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2015</rights><rights>Revelli et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-f11db5261ba7dd079aec74584cfa06bb2c03a2bb6d03cfd345702ccbfd5e333a3</citedby><cites>FETCH-LOGICAL-c494t-f11db5261ba7dd079aec74584cfa06bb2c03a2bb6d03cfd345702ccbfd5e333a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514947/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514947/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26209525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Revelli, Alberto</creatorcontrib><creatorcontrib>Pettinau, Grazia</creatorcontrib><creatorcontrib>Basso, Gemma</creatorcontrib><creatorcontrib>Carosso, Andrea</creatorcontrib><creatorcontrib>Ferrero, Alessandro</creatorcontrib><creatorcontrib>Dallan, Cecilia</creatorcontrib><creatorcontrib>Canosa, Stefano</creatorcontrib><creatorcontrib>Gennarelli, Gianluca</creatorcontrib><creatorcontrib>Guidetti, Daniela</creatorcontrib><creatorcontrib>Filippini, Claudia</creatorcontrib><creatorcontrib>Benedetto, Chiara</creatorcontrib><title>Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population</title><title>Reproductive biology and endocrinology</title><addtitle>Reprod Biol Endocrinol</addtitle><description>The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug.
Eight hundred forty-eight (848) IVF patients classified as expected "poor" or "normal" responders according to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh embryos was calculated by stratifying patients according to the number of retrieved oocytes (1-2, 3-4, 5-6, 7-8, >8).
Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly better pregnancy rate outcome. Patients' characteristics did not significantly differ between the two groups and the better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis, that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively.
When comparing patients with the same number of retrieved oocytes under real-life circumstances, the association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial receptivity could be involved.</description><subject>Adult</subject><subject>Comparative analysis</subject><subject>Female</subject><subject>Follicle Stimulating Hormone - pharmacology</subject><subject>Follicle Stimulating Hormone - therapeutic use</subject><subject>Genetic aspects</subject><subject>Gonadotropin</subject><subject>Humans</subject><subject>Luteinizing Hormone - pharmacology</subject><subject>Luteinizing Hormone - therapeutic use</subject><subject>Menopause</subject><subject>Menotropins - pharmacology</subject><subject>Menotropins - therapeutic use</subject><subject>Oocyte Retrieval - methods</subject><subject>Oocytes - drug effects</subject><subject>Ovulation Induction - methods</subject><subject>Pharmaceutical industry</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Pregnancy Rate</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1477-7827</issn><issn>1477-7827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkstu1DAUhiMEohd4ADbIEhs2GewkzoUFUjWiHaRBXRTW1olz0nHl2MGXqfqiPA8ezbR0EMrC0Tn__9k-_rPsHaMLxtr6k2dFx9ucMp5T2tK8fpGdsqpp8qYtmpfP_k-yM-_vKC2SrH6dnRR1QTte8NPs99Ka4KzWOJDrLTgFhtwENUUNQVlD7lXYEIfSTr0yYEJ-ebMis47-qLheka1fkE2ckv07GjtD9KDJlTUw2MSflSE9-LRJYoYNEhOnHh2xY-IEp3C7a1n5ENB_TiUfdfBkdHYiQJyNQRkkUiujZMLODmRQEkmipjaCzrUakcx2Ppz7TfZqBO3x7WE9z35efv2xXOXr66tvy4t1LquuCvnI2NDzomY9NMNAmw5QNhVvKzkCrfu-kLSEou_rgZZyHMqKN7SQsh8HjmVZQnmefdlz59hPOEhMwwQtZqcmcA_CghLHHaM24tZuRcVZOkGTAB8PAGd_RfRBTMpL1BoM2ugFq7uu6mjHuiT98I_0zkZn0vUES49MOW_a8q_qFjQKZcY0fpA7qLjgFeO0Zt1u28V_VOkbcFLSGhxVqh8Z2N4gnfXe4fh0R0bFLoxiH0aRwih2YRR18rx_Ppwnx2P6yj9XvN_j</recordid><startdate>20150725</startdate><enddate>20150725</enddate><creator>Revelli, Alberto</creator><creator>Pettinau, Grazia</creator><creator>Basso, Gemma</creator><creator>Carosso, Andrea</creator><creator>Ferrero, Alessandro</creator><creator>Dallan, Cecilia</creator><creator>Canosa, Stefano</creator><creator>Gennarelli, Gianluca</creator><creator>Guidetti, Daniela</creator><creator>Filippini, Claudia</creator><creator>Benedetto, Chiara</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150725</creationdate><title>Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population</title><author>Revelli, Alberto ; Pettinau, Grazia ; Basso, Gemma ; Carosso, Andrea ; Ferrero, Alessandro ; Dallan, Cecilia ; Canosa, Stefano ; Gennarelli, Gianluca ; Guidetti, Daniela ; Filippini, Claudia ; Benedetto, Chiara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-f11db5261ba7dd079aec74584cfa06bb2c03a2bb6d03cfd345702ccbfd5e333a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Comparative analysis</topic><topic>Female</topic><topic>Follicle Stimulating Hormone - pharmacology</topic><topic>Follicle Stimulating Hormone - therapeutic use</topic><topic>Genetic aspects</topic><topic>Gonadotropin</topic><topic>Humans</topic><topic>Luteinizing Hormone - pharmacology</topic><topic>Luteinizing Hormone - therapeutic use</topic><topic>Menopause</topic><topic>Menotropins - pharmacology</topic><topic>Menotropins - therapeutic use</topic><topic>Oocyte Retrieval - methods</topic><topic>Oocytes - drug effects</topic><topic>Ovulation Induction - methods</topic><topic>Pharmaceutical industry</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Pregnancy Rate</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Revelli, Alberto</creatorcontrib><creatorcontrib>Pettinau, Grazia</creatorcontrib><creatorcontrib>Basso, Gemma</creatorcontrib><creatorcontrib>Carosso, Andrea</creatorcontrib><creatorcontrib>Ferrero, Alessandro</creatorcontrib><creatorcontrib>Dallan, Cecilia</creatorcontrib><creatorcontrib>Canosa, Stefano</creatorcontrib><creatorcontrib>Gennarelli, Gianluca</creatorcontrib><creatorcontrib>Guidetti, Daniela</creatorcontrib><creatorcontrib>Filippini, Claudia</creatorcontrib><creatorcontrib>Benedetto, Chiara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Reproductive biology and endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Revelli, Alberto</au><au>Pettinau, Grazia</au><au>Basso, Gemma</au><au>Carosso, Andrea</au><au>Ferrero, Alessandro</au><au>Dallan, Cecilia</au><au>Canosa, Stefano</au><au>Gennarelli, Gianluca</au><au>Guidetti, Daniela</au><au>Filippini, Claudia</au><au>Benedetto, Chiara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population</atitle><jtitle>Reproductive biology and endocrinology</jtitle><addtitle>Reprod Biol Endocrinol</addtitle><date>2015-07-25</date><risdate>2015</risdate><volume>13</volume><issue>1</issue><spage>77</spage><epage>77</epage><pages>77-77</pages><artnum>77</artnum><issn>1477-7827</issn><eissn>1477-7827</eissn><abstract>The association of recombinant FSH (rFSH) plus recombinant LH (rLH) is currently used for Controlled Ovarian Stimulation (COS) in human IVF, but its efficacy has, to date, not yet been compared to that of human Menopausal Gonadotropin (hMG), the FSH + LH activity-containing urinary drug.
Eight hundred forty-eight (848) IVF patients classified as expected "poor" or "normal" responders according to antral follicle count (AFC) and basal (day 3) FSH were treated with rFSH + rLH (2:1 ratio, n = 398, Group A) or hMG (n = 450, Group B). Data were collected under real-life practice circumstances and the pregnancy rate with fresh embryos was calculated by stratifying patients according to the number of retrieved oocytes (1-2, 3-4, 5-6, 7-8, >8).
Overall, the pregnancy rate in both groups progressively improved according to the number of oocytes retrieved. When comparing patients within the same subgroup of oocyte yield, Group A and B showed a comparable outcome up to the reported highest yield (>8). When more than 8 oocytes were available, Group A had a significantly better pregnancy rate outcome. Patients' characteristics did not significantly differ between the two groups and the better outcome in the best responding patients in Group A was confirmed by a multivariable logistic regression analysis, that showed that both the use of rFSH + rLH and the total number of retrieved oocytes increased the probability of pregnancy with odd ratio (OR) of 1.628 and 1.083, respectively.
When comparing patients with the same number of retrieved oocytes under real-life circumstances, the association of rFSH + rLH results in a significantly higher pregnancy rate than hMG when more than 8 oocytes are retrieved. The reason(s) for this are unknown, but a more favorable effect on oocyte quality and/or endometrial receptivity could be involved.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>26209525</pmid><doi>10.1186/s12958-015-0080-6</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1477-7827 |
| ispartof | Reproductive biology and endocrinology, 2015-07, Vol.13 (1), p.77-77, Article 77 |
| issn | 1477-7827 1477-7827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4514947 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Adult Comparative analysis Female Follicle Stimulating Hormone - pharmacology Follicle Stimulating Hormone - therapeutic use Genetic aspects Gonadotropin Humans Luteinizing Hormone - pharmacology Luteinizing Hormone - therapeutic use Menopause Menotropins - pharmacology Menotropins - therapeutic use Oocyte Retrieval - methods Oocytes - drug effects Ovulation Induction - methods Pharmaceutical industry Pregnancy Pregnancy Outcome Pregnancy Rate Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use Treatment Outcome |
| title | Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T21%3A58%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Controlled%20Ovarian%20Stimulation%20with%20recombinant-FSH%20plus%20recombinant-LH%20vs.%20human%20Menopausal%20Gonadotropin%20based%20on%20the%20number%20of%20retrieved%20oocytes:%20results%20from%20a%20routine%20clinical%20practice%20in%20a%20real-life%20population&rft.jtitle=Reproductive%20biology%20and%20endocrinology&rft.au=Revelli,%20Alberto&rft.date=2015-07-25&rft.volume=13&rft.issue=1&rft.spage=77&rft.epage=77&rft.pages=77-77&rft.artnum=77&rft.issn=1477-7827&rft.eissn=1477-7827&rft_id=info:doi/10.1186/s12958-015-0080-6&rft_dat=%3Cgale_pubme%3EA541506197%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1782055783&rft_id=info:pmid/26209525&rft_galeid=A541506197&rfr_iscdi=true |